老年痴呆症症治疗市场－全球产业规模、份额、趋势、机会、预测：按产品类型、最终用户、地区和竞争对手划分，2021-2031年

全球阿兹海默症治疗市场预计将从 2025 年的 49.2 亿美元成长到 2031 年的 77.7 亿美元，复合年增长率为 7.92%。

阿兹海默症治疗药物是指一系列旨在改善该疾病病理或缓解相关症状的药物。该市场的成长主要受全球人口老化加剧以及由此导致的失智症盛行率上升的驱动，这使得对有效临床干预措施的需求变得特别迫切。此外，该疾病带来的巨大经济负担也推动了医疗需求并刺激了研究投入。根据阿兹海默症协会预测，到2025年，美国阿兹海默症和其他失智症患者的总费用预计将达到3,840亿美元。

儘管存在这些成长要素，但由于候选药物在临床试验中的高脱落率，该领域仍面临许多重大挑战。疾病复杂的生物学特性导致科学研究失败频传，进而造成监管核准延迟和研发成本飙升。这种临床试验屡屡受挫的趋势，为製药研发公司和投资者创造了不稳定的环境，严重阻碍了创新疗法在全球市场的快速扩张和商业化。

市场驱动因素

全球人口老化及其导致的疾病盛行率上升是阿兹海默症治疗领域发展的主要驱动力。随着全球平均寿命的延长，神经退化性疾病的发生率激增，对有效药物介入的需求也日益迫切。这种人口结构的变化迫使医疗卫生系统引入能够控制症状并延缓疾病进展的治疗方法。根据世界卫生组织（世卫组织）2024年3月发布的《失智症》概况介绍，目前全球有超过5,500万人患有失智症，每年新增病例约1,000万例。如此迅速成长的患者群体需要广泛推广治疗方法，这不仅能确保研发公司的持续收入，还能推动失智症护理在全球卫生政策中占据战略优先地位。

同时，新型疾病修正治疗的商业化和临床研发管线的扩展正对市场产生显着影响。製药公司正日益将研发重心从对症治疗转向靶向潜在的疾病机制，例如β-淀粉样蛋白斑块，这提振了投资者信心并推动了新产品的上市。公共部门为加速药物发现的投资，为此创新发展轨迹提供了强而有力的支持。例如，根据美国国家老化研究所 (NIA) 的报告，2024 年联邦预算中新增了1 亿美元用于阿兹海默症及相关失智症的研究。这项研究规模庞大，阿兹海默症协会 2024 年 5 月的报告显示，目前有 164 种药物正在进行临床试验，显示治疗方案的未来前景广阔。

市场挑战

临床试验中候选药物的高脱落率是全球阿兹海默症治疗市场成长的一大障碍。这项挑战主要源自于疾病复杂的生物学特性，在从临床前模型过渡到人体试验的过程中，常常会出现意想不到的疗效不佳。当前景看好的候选药物在后期临床试验中失败时，研发公司将遭受巨额损失，并面临漫长的研发週期。这种反覆出现的模式造成了不稳定的环境，阻碍了持续的资本投入，迫使製药公司采取极其保守的策略，最终减缓了创新步伐和新产品的市场进入速度。

这些临床试验挫折的直接后果是，具有商业性可行性的治疗方法研发管线有限，这限制了该领域的产生收入机会。研究成果与监管核准之间的差距依然显着，造成了供应瓶颈。根据阿兹海默症协会预测，到2024年，将有164种阿兹海默症药物进入临床试验阶段，但由于开发平臺固有的高失败率，儘管研究工作正在积极开展，但预计只有少数药物能够克服研发障碍，真正实现市场扩张。

市场趋势

血液生物标记的应用正在改变患者分层方式，取代了PET扫描和脑脊髓液分析等昂贵且有创的诊断方法。这种向更容易取得的血浆诊断工具的转变将克服临床试验中患者招募缓慢这一重大瓶颈，从而实现大规模的疾病早期检测，这对于及时用药至关重要。诊断准确性的提高将有助于快速识别适合疾病修正治疗的患者，直接影响市场渗透率和保险报销模式。根据阿兹海默症协会2024年7月发布的新闻稿，一项关键研究表明，一种名为APS2的特定血液检测在识别阿兹海默症病理方面具有约90%的准确率，显着优于使用传统评估方法的基层医疗医生63%的准确率。

同时，随着人们对神经退化疾病代谢因子的认识不断提高，製药业正在进行一项策略性转变，即重新利用GLP-1促效剂及其代谢物。製药公司正在积极研究这些核准用于治疗糖尿病和肥胖症的药物，探索其在传统淀粉样蛋白标靶治疗之外，发挥减轻神经发炎和神经保护作用的潜力。这一趋势代表了一种经济有效的途径，可以透过利用安全性已验证的药物，实现治疗方案的多元化，并降低新药研发的风险。根据2024年12月发表在BioSpace上的一篇报导，一项真实世界临床研究表明，与未接受Semaglutide肽治疗的患者相比，接受索玛鲁肽治疗的2型糖尿病患者患阿兹海默症的风险降低了40%至70%。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：老年痴呆症症治疗的全球市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 产品种类（胆碱酯酶抑制剂{多奈哌齐、Galantamine、Rivastigmine}、NMDA受体拮抗剂、复方药物、正在研药物）
  • 依最终用户（医院药局、零售药局、电子商务）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美老年痴呆症治疗药物市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲老年痴呆症治疗药物市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区老年痴呆症治疗药物市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲老年痴呆症治疗药物市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美老年痴呆症症治疗市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球老年痴呆症治疗市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Eisai Co., Ltd.
• Novartis AG
• AbbVie Inc.（Allergan Plc.）
• Adamas Pharmaceuticals, Inc.
• H. Lundbeck A/S
• Biogen Inc.
• AC Immune SA
• F. Hoffmann La Roche Ltd.
• Daiichi Sankyo Company Limited
• Johnson & Johnson

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Alzheimer's Therapeutics Market is projected to expand from USD 4.92 Billion in 2025 to USD 7.77 Billion by 2031, reflecting a compound annual growth rate (CAGR) of 7.92%. Alzheimer's therapeutics consist of pharmaceutical agents developed to modify the disease's pathology or alleviate symptoms associated with the condition. The market is primarily propelled by the growing global elderly population and the corresponding increase in dementia prevalence, which creates a critical need for effective clinical interventions. Additionally, the substantial economic strain caused by the disease fuels the demand for medical treatments and stimulates research investment; according to the Alzheimer's Association, the total cost of care for individuals with Alzheimer's and other dementias in the United States is expected to reach $384 billion in 2025.

Despite these growth factors, the sector encounters a major obstacle due to the high attrition rate of drug candidates during clinical trials. The complex biology of the disease frequently results in scientific failures that delay regulatory approval and escalate development costs. This trend of clinical setbacks creates a precarious landscape for pharmaceutical developers and investors, significantly hindering the rapid expansion and commercialization of innovative therapeutic solutions in the global market.

Market Driver

The expanding global geriatric population and the resulting rise in disease prevalence act as the primary catalysts for the growth of the Alzheimer's therapeutics sector. As life expectancy increases worldwide, the incidence of neurodegenerative conditions is surging, generating an urgent and sustained demand for effective pharmaceutical interventions. This demographic shift exerts immense pressure on healthcare systems to adopt treatments capable of managing symptoms or slowing disease progression. According to a March 2024 'Dementia' fact sheet by the World Health Organization, there are currently over 55 million people living with dementia globally, with nearly 10 million new cases arising annually. This rapidly growing patient base requires the widespread availability of therapeutic agents, ensuring continuous revenue for developers and driving the strategic prioritization of dementia care in global health policies.

Simultaneously, the market is significantly influenced by the commercialization of new disease-modifying therapies and the broadening of the clinical pipeline. Pharmaceutical companies are increasingly shifting focus from symptomatic relief to targeting underlying disease mechanisms, such as amyloid-beta plaques, which fosters renewed investor confidence and drives product launches. This innovation trajectory is heavily supported by public sector investment designed to accelerate discovery; for instance, the National Institute on Aging reported that 2024 federal appropriations provided a $100 million increase for Alzheimer's and related dementias research. The scale of this research is extensive, with the Alzheimer's Association's May 2024 report noting 164 agents currently in clinical trials, indicating a robust future for therapeutic options.

Market Challenge

The high attrition rate of drug candidates during clinical trials serves as a significant barrier to the growth of the global Alzheimer's therapeutics market. This challenge arises largely from the complex biological nature of the disease, which often results in unexpected efficacy failures as pharmaceutical agents move from preclinical models to human testing. When promising candidates fail in late-stage trials, developers suffer massive financial losses and face extended development timelines. This recurring pattern creates a volatile environment that discourages sustained capital investment and compels pharmaceutical companies to adopt highly conservative strategies, ultimately slowing the pace of innovation and the market entry of new products.

The direct result of these clinical setbacks is a restricted pipeline of commercially viable treatments, which limits revenue generation opportunities for the sector. The disparity between research efforts and successful regulatory approvals remains significant, creating a supply bottleneck. Although the Alzheimer's Association reported 164 agents in clinical trials for Alzheimer's disease in 2024, the high failure rate inherent to this pipeline means that despite the volume of active research, only a small fraction of these agents are likely to overcome development hurdles and contribute to actual market expansion.

Market Trends

The adoption of blood-based biomarkers is transforming patient stratification by replacing expensive and invasive diagnostic methods such as PET scans and cerebrospinal fluid analysis. This shift toward accessible plasma diagnostic tools resolves the critical bottleneck of slow clinical trial recruitment and enables earlier disease detection on a population scale, which is vital for the timely administration of therapeutics. Enhanced diagnostic precision allows for the rapid identification of suitable candidates for disease-modifying therapies, directly influencing market uptake and payer reimbursement models. According to a July 2024 press release by the Alzheimer's Association, a pivotal study demonstrated that a specific blood test known as APS2 was approximately 90% accurate in identifying Alzheimer's pathology, significantly outperforming primary care physicians who were only 63% accurate using traditional evaluation methods.

Concurrently, the sector is witnessing a strategic pivot toward repurposing GLP-1 agonists and metabolic agents, driven by the increasing recognition of the metabolic components of neurodegeneration. Pharmaceutical developers are actively investigating these agents, originally approved for diabetes and obesity, for their potential to reduce neuroinflammation and offer neuroprotection beyond traditional amyloid-targeting mechanisms. This trend represents a cost-efficient pathway to diversify therapeutic portfolios and mitigate the risks associated with novel drug development by leveraging agents with established safety profiles. According to a December 2024 BioSpace article, a real-world study indicated that patients with type 2 diabetes prescribed semaglutide showed a 40% to 70% reduction in the risk of being diagnosed with Alzheimer's disease compared to unexposed patient groups.

Key Market Players

• Eisai Co., Ltd.
• Novartis AG
• AbbVie Inc. (Allergan Plc.)
• Adamas Pharmaceuticals, Inc.
• H. Lundbeck A/S
• Biogen Inc.
• AC Immune SA
• F. Hoffmann La Roche Ltd.
• Daiichi Sankyo Company Limited
• Johnson & Johnson

Report Scope

In this report, the Global Alzheimer's Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Alzheimer's Therapeutics Market, By Product Type

• Cholinesterase Inhibitors {Donepezil, Galantamine, Rivastigmine}
• NMDA Receptor Antagonist
• Combination Drugs
• Pipeline Drugs

Alzheimer's Therapeutics Market, By End User

• Hospital Pharmacy
• Retail Pharmacy
• E-commerce

Alzheimer's Therapeutics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Alzheimer's Therapeutics Market.

Available Customizations:

Global Alzheimer's Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Alzheimer's Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type (Cholinesterase Inhibitors {Donepezil, Galantamine, Rivastigmine}, NMDA Receptor Antagonist, Combination Drugs, Pipeline Drugs)
  • 5.2.2. By End User (Hospital Pharmacy, Retail Pharmacy, E-commerce)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Alzheimer's Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product Type
  • 6.2.2. By End User
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Alzheimer's Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product Type
      • 6.3.1.2.2. By End User
  • 6.3.2. Canada Alzheimer's Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product Type
      • 6.3.2.2.2. By End User
  • 6.3.3. Mexico Alzheimer's Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product Type
      • 6.3.3.2.2. By End User

7. Europe Alzheimer's Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product Type
  • 7.2.2. By End User
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Alzheimer's Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product Type
      • 7.3.1.2.2. By End User
  • 7.3.2. France Alzheimer's Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product Type
      • 7.3.2.2.2. By End User
  • 7.3.3. United Kingdom Alzheimer's Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product Type
      • 7.3.3.2.2. By End User
  • 7.3.4. Italy Alzheimer's Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product Type
      • 7.3.4.2.2. By End User
  • 7.3.5. Spain Alzheimer's Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product Type
      • 7.3.5.2.2. By End User

8. Asia Pacific Alzheimer's Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product Type
  • 8.2.2. By End User
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Alzheimer's Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product Type
      • 8.3.1.2.2. By End User
  • 8.3.2. India Alzheimer's Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product Type
      • 8.3.2.2.2. By End User
  • 8.3.3. Japan Alzheimer's Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product Type
      • 8.3.3.2.2. By End User
  • 8.3.4. South Korea Alzheimer's Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product Type
      • 8.3.4.2.2. By End User
  • 8.3.5. Australia Alzheimer's Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product Type
      • 8.3.5.2.2. By End User

9. Middle East & Africa Alzheimer's Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product Type
  • 9.2.2. By End User
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Alzheimer's Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product Type
      • 9.3.1.2.2. By End User
  • 9.3.2. UAE Alzheimer's Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product Type
      • 9.3.2.2.2. By End User
  • 9.3.3. South Africa Alzheimer's Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product Type
      • 9.3.3.2.2. By End User

10. South America Alzheimer's Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product Type
  • 10.2.2. By End User
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Alzheimer's Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product Type
      • 10.3.1.2.2. By End User
  • 10.3.2. Colombia Alzheimer's Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product Type
      • 10.3.2.2.2. By End User
  • 10.3.3. Argentina Alzheimer's Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product Type
      • 10.3.3.2.2. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Alzheimer's Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Eisai Co., Ltd.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Novartis AG
• 15.3. AbbVie Inc. (Allergan Plc.)
• 15.4. Adamas Pharmaceuticals, Inc.
• 15.5. H. Lundbeck A/S
• 15.6. Biogen Inc.
• 15.7. AC Immune SA
• 15.8. F. Hoffmann La Roche Ltd.
• 15.9. Daiichi Sankyo Company Limited
• 15.10. Johnson & Johnson

16. Strategic Recommendations

17. About Us & Disclaimer